|Bid||0.0610 x 38103100|
|Ask||0.0620 x 63288200|
|Day's range||0.0610 - 0.0640|
|52-week range||0.0530 - 0.0950|
|Beta (5Y monthly)||2.62|
|PE ratio (TTM)||N/A|
|Earnings date||20 Feb 2023 - 24 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
As an investor, mistakes are inevitable. But really big losses can really drag down an overall portfolio. So spare a...
Phase 1 study of BBI-02 progressing well and expect to initiate MAD part of the study next month On track to report SAD and MAD topline results from BBI-02 Phase 1 study by early 2023 Development of BBI-10 and next-generation kinase inhibitors advancing through early preclinical stage studies BOULDER, Colo., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developin